32.88

0.12% -0.04

Zenas Biopharma Inc (ZBIO)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

$32.92

Aprire:

$32.66

Volume 24 ore:

452.69K

Relative Volume:

0.55

Capitalizzazione di mercato:

$2.14B

Reddito:

$10.00M

Utile/perdita netta:

$-425.15M

Rapporto P/E:

-3.6146

EPS:

-9.0964

Flusso di cassa netto:

$-210.48M

1 W Prestazione:

+5.15%

1M Prestazione:

+4.65%

6M Prestazione:

+27.34%

1 anno Prestazione:

+93.64%

Intervallo 1D:

$32.38

$33.29

Intervallo di 1 settimana:

$29.88

$33.66

Portata 52W:

$13.50

$44.60

Zenas Biopharma Inc Stock (ZBIO) Company Profile

Nome

Zenas Biopharma Inc

Settore

Healthcare (1074)

Industria

Biotechnology (600)

Telefono

857-271-2954

Indirizzo

852 WINTER STREET, SUITE 250, WALTHAM

Dipendente

167

Cinguettio

Prossima data di guadagno

2026-08-11

Ultimi documenti SEC

ZBIO's Discussions on Twitter

Compare ZBIO vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ZBIO Zenas Biopharma Inc	32.88	2.06B	10.00M	-425.15M	-210.48M	-9.0964
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-05	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-03-20	Iniziato	Wedbush	Outperform
2025-02-04	Iniziato	Wolfe Research	Outperform
2024-12-16	Iniziato	H.C. Wainwright	Buy
2024-11-05	Iniziato	Rodman & Renshaw	Buy
2024-10-08	Iniziato	Citigroup	Buy
2024-10-08	Iniziato	Guggenheim	Buy
2024-10-08	Iniziato	Jefferies	Buy
2024-10-08	Iniziato	Morgan Stanley	Overweight

Mostra tutto

Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie

Aug 19, 2026

Zenas BioPharma (ZBIO) holder sells 673,755 shares in open-market trade - Stock Titan

Aug 19, 2026

Zenas BioPharma (ZBIO) affiliate plans August 2026 share sale - Stock Titan

Aug 19, 2026

Zenas BioPharma (ZBIO) Institutional Ownership 2026 - MarketBeat

Aug 19, 2026

Aug 18, 2026

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Aug 18, 2026

New Zenas BioPharma hires receive stock awards vesting through 2030 - Stock Titan

Aug 18, 2026

HC Wainwright Predicts Higher Earnings for Zenas BioPharma - MarketBeat

Aug 18, 2026

Aug 17, 2026

SR One's stake in Zenas BioPharma (ZBIO) drops over 1 point without selling - Stock Titan

Aug 17, 2026

Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Raises Target Price to $32 - Moomoo

Aug 17, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 17, 2026

Aug 15, 2026

ZBIO Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline for Clinical-Stage BiotechDividend Growth Analysis - Vinanet

Aug 15, 2026

Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO - MarketBeat

Aug 15, 2026

Aug 14, 2026

Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim - MarketBeat

Aug 14, 2026

Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush - MarketBeat

Aug 14, 2026

Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership ChangesWhat's Changed - simplywall.st

Aug 14, 2026

Zenas BioPharma, Inc. Announces Chief Financial Officer Changes, Effective September 30, 2026 - marketscreener.com

Aug 13, 2026

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings - MarketBeat

Aug 13, 2026

Zenas BioPharma Q2 Results: EPS Misses, Sales Fall 95% - scanx.trade

Aug 13, 2026

Zenas BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

Form 8K Zenas Biopharma Inc For: 13 August By Investing.com - Investing.com Canada

Aug 13, 2026

Zenas BioPharma's Q2 Net Loss Widens; CFO to Step Down - marketscreener.com

Aug 13, 2026

Earnings Flash (ZBIO) Zenas BioPharma Posts Q2 Loss $1.77 a Share, vs. FactSet Est of $1.12 Loss - marketscreener.com

Aug 13, 2026

Zenas BioPharma, Inc. 2026: Revenue $1M, Net income ($111.46M), EPS ($1.77) — 10-Q Summary - TradingView

Aug 13, 2026

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times

Aug 13, 2026

Earnings Flash (ZBIO) Zenas BioPharma, Inc. Reports Q2 Revenue $1.0M - marketscreener.com

Aug 13, 2026

Zenas BioPharma Reports $111.5 Million Second-Quarter Net Loss - Quiver Quantitative

Aug 13, 2026

Aug 12, 2026

Zenas BioPharma (ZBIO) Slides 3.55% to $31.29 as Biotech Sentiment Turns CautiousTotal Put Call - dars.gov.et

Aug 12, 2026

Zenas BioPharma (ZBIO) Edges Higher to $32.44 as Biotech Momentum BuildsMA Cross Alert - Vinanet

Aug 12, 2026

Aug 11, 2026

Zenas BioPharma (ZBIO) Rises 1.41% to $32.44 as Shares Hold Above Key SupportSynthetic Long - vinanet.vn

Aug 11, 2026

Aug 08, 2026

Zenas BioPharma (ZBIO) Holds Gains Above $32 as Bullish Momentum BuildsIndex Put Call - dars.gov.et

Aug 08, 2026

Aug 07, 2026

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, In - The National Law Review

Aug 07, 2026